Annual Drug Patent Expirations for SEEBRI
Seebri is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug.
Drug patent litigation for SEEBRI.
This drug has two hundred and ninety-eight patent family members in forty-one countries.
The generic ingredient in SEEBRI is glycopyrrolate. One supplier is listed for this compound. Additional details are available on the glycopyrrolate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
